Drug Profile
FATE NK100
Alternative Names: FATE-NK100Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Fate Therapeutics; University of Minnesota
- Developer Fate Therapeutics; Masonic Cancer Center
- Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 10 Mar 2021 Fate Therapeutics completes a phase I trial in Peritoneal cancer, Fallopian tube cancer and Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT03213964)
- 15 Dec 2020 Fate Therapeutics completes a phase I trial in Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03319459)
- 01 Dec 2020 Fate Therapeutics completes a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in US (NCT03081780)